News | September 18, 2024
Lupin inks licensing agreement with Takeda to commercialize Vonoprazan
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
Fluoxetine Tabs 60 mg approval solidifies the company's position in the molecule by complementing the recent approval in April 2024 for Fluoxetine 10 mg and 20 mg tablets and Fluoxetine capsules
The sANDA was submitted as “Prior Approval Supplement” for addition of an alternate drug product manufacturing, labeling, packaging, and testing facility
Vonoprazan is used in the treatment of disorders related to Gastroesophageal Reflux Disease (GERD)
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
Lonza Bend (US) upgrades capabilities in early phase clinical manufacturing services with the addition of bottling and labeling equipment
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
